DarioHealth

The company's business model has transitioned from a direct-to-consumer (B2C) approach to primarily a business-to-business-to-consumer (B2B2C) model, targeting employers, health plans, and pharmaceutical companies. Revenue is generated through recurring subscription fees for its Software as a Service (SaaS) platform, with a smaller portion coming from initial device sales and direct consumer subscriptions. This strategy aims to reduce user acquisition costs and secure stable, high-margin revenue streams through multi-year contracts. The platform serves a diverse client base, including Fortune 100 employers and major national health plans like Aetna.

DarioHealth offers an integrated suite of solutions that address a range of conditions on a single platform, including diabetes, hypertension, weight management, musculoskeletal (MSK) pain, and behavioral health. The platform combines connected medical devices, such as a blood glucose monitor that plugs into a smartphone, a blood pressure cuff, and the Upright Go S sensor for posture, with a highly-rated mobile application (4.9 stars on the Apple App Store). It leverages AI and billions of data points to deliver personalized insights, targeted interventions, and real-time support from human coaches. This multi-condition approach is a key differentiator, designed to provide holistic care and simplify health management for users.

Significant milestones include receiving FDA clearance for its blood glucose monitoring system in 2015 and going public on the NASDAQ in 2013. The company has expanded its offerings through strategic acquisitions, including Upright (MSK) and wayForward (behavioral health) in 2021, Physimax (computer vision for MSK) in 2022, and Twill (digital-led care) in 2024. These acquisitions have been instrumental in creating a comprehensive platform that addresses physical and mental well-being, including recent expansions into maternal health and GLP-1 support programs.